Re: ZEN-3694 mCRPC Trial Status
in response to
by
posted on
Nov 18, 2017 07:45PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Thanks Bear.
To be clear, it is only the single agent arm for mCRPC that has been completed. The combination arm is still ongoing and the breast cancer arm has yet to begin.
tada